文献速递肝病

塞拉德尔治疗减少原发性胆汁性胆管炎患者的IL-31和瘙痒

Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.
PubMed 文献 · Hepatology · 2023-12-20

ENHANCE研究显示,原发性胆汁性胆管炎患者接受塞拉德尔5mg或10mg治疗3个月后,血清IL-31分别降低30%和52%,而安慰剂组升高31%。基线IL-31与瘙痒数值评定量表及胆汁酸水平相关,IL-31与胆汁酸的变化高度相关,提示塞拉德尔抗瘙痒机制。

要点

  • 塞拉德尔5mg和10mg组IL-31分别降低30%和52%,安慰剂组升高31%。
  • 瘙痒临床有意义改善者IL-31降低幅度大于无改善者。
  • 塞拉德尔10mg组IL-31与总胆汁酸变化强相关(r=0.63)。

核心结论

  • 塞拉德尔降低原发性胆汁性胆管炎患者血清IL-31和胆汁酸水平。
  • IL-31与胆汁酸的降低彼此密切相关,且与瘙痒改善相关,提示塞拉德尔抗瘙痒作用的机制。

研究设计与样本

  • ENHANCE研究,患者每日口服安慰剂(n=55)、塞拉德尔5mg(n=53)或10mg(n=53)治疗3个月,另设健康志愿者(n=55)。

主要发现

  • 基线IL-31与瘙痒数值评定量表(NRS,0-10)相关(r=0.54,p<0.0001),与总胆汁酸相关(r=0.54,p<0.0001),与结合胆汁酸相关(高达0.64,p<0.0001)。
  • 塞拉德尔5mg组IL-31降低30%(p=0.0003),10mg组降低52%(p<0.0001),安慰剂组升高31%。
  • 瘙痒临床有意义改善(NRS降低≥2)的患者较无改善(NRS降低<2)者IL-31降低幅度更大,呈剂量依赖性。
  • 塞拉德尔10mg组IL-31与总胆汁酸变化强相关(r=0.63,p<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Pruritus is a debilitating symptom for many people living with primary biliary cholangitis (PBC). In studies with seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, patients with PBC experienced significant improvement in pruritus and reduction of serum bile acids. Interleukin-31 (IL-31) is a cytokine known to mediate pruritus, and blocking IL-31 signaling provides relief in pruritic skin diseases. This study examined the connection between seladelpar's antipruritic effects and IL-31 and bile acid levels in patients with PBC. APPROACH AND RESULTS: IL-31 levels were quantified in serum samples from the ENHANCE study of patients with PBC receiving daily oral doses of placebo (n = 55), seladelpar 5 mg (n = 53) or 10 mg (n = 53) for 3 months, and for healthy volunteers (n = 55). IL-31 levels were compared with pruritus using a numerical rating scale (NRS, 0-10) and with bile acid levels. Baseline IL-31 levels closely correlated with pruritus NRS ( r = 0.54, p < 0.0001), and total ( r = 0.54, p < 0.0001) and conjugated bile acids (up to 0.64, p < 0.0001). Decreases in IL-31 were observed with seladelpar 5 mg (-30%, p = 0.0003) and 10 mg (-52%, p < 0.0001) versus placebo (+31%). Patients with clinically meaningful improvement in pruritus (NRS ≥ 2 decrease) demonstrated greater dose-dependent reductions in IL-31 compared to those without pruritus improvement (NRS < 2 decrease). Strong correlations were observed for the changes between levels of IL-31 and total bile acids ( r = 0.63, p < 0.0001) in the seladelpar 10 mg group. CONCLUSIONS: Seladelpar decreased serum IL-31 and bile acids in patients with PBC. The reductions of IL-31 and bile acids correlated closely with each other and pruritus improvement, suggesting a mechanism to explain seladelpar's antipruritic effects.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kremer AE, Mayo MJ, Hirschfield GM, et al. Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology. 2023. PMID: 38117036. doi:10.1097/HEP.0000000000000728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。